Shilpa Medicare Ltd Share Price
(SHILPAMED)
₹676.5▲7.31%
as on 01:50PM, 18 Mar 2025
🔔 Partnership Alert
Shilpa Medicare's subsidiary, Shilpa Biologicals, partners with mAbTree Biologics AG to co-develop a novel immuno-oncology therapy.
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | -1.78 % |
3 Month Return | -24.08 % |
1 Year Return | + 37.18 % |
Market Stats | |
Previous Close | ₹630.40 |
Open | ₹676.80 |
Volume | 12.76L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹6,164.74Cr |
P/E Ratio
67.35
PEG Ratio
7.14
Market Cap
₹6,164.74 Cr
P/B Ratio
1.87
EPS
3.68
Dividend Yield
0Sector
Pharmaceuticals
ROE
1.59
based on 2 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 2 analysts offering long term price targets for Shilpa Medicare. An average target of ₹1208
Source: S&P Global Market Intelligence
Shilpa Medicare price forecast by 2 analysts
Upside of91.62%
High
₹1525
Target
₹1208.00
Low
₹891
Shilpa Medicare target price ₹1208, a slight upside of 91.62% compared to current price of ₹676.5. According to 2 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Shilpa Medicare revenue growth forecast
Expected growth rate Q1, FY2027:0
Forecast
Actual
Including amortisation and stock based compensations
Shilpa Medicare EPS growth forecast
EPS estimate Q1, FY2027:0
Forecast
Actual
Source: S&P Global Market Intelligence
Today's Timeline - Invalid Date
06:19 AM
-Shilpa Biologicals enters binding term sheet with mAbTree Biologics for developing a new biological entity.
09:43 AM
-Shilpa Medicare shares rise 2% after subsidiary partners with mAbTree Biologics for cancer drug development.
11:11 AM
-Shilpa Medicare stock soars 10.46% following strategic partnership announcement with mAbTree Biologics for immuno-oncology therapy.
Today's Timeline - Invalid Date
12:01 PM
-Shilpa Medicare shares surge 10% as subsidiary partners with mAbTree Biologics for novel cancer therapy.
12:32 PM
-Shilpa Medicare stock rises 9.70% after announcing partnership with mAbTree Biologics for immuno-oncology therapy.
Shilpa Medicare Achieves Second Clean USFDA Inspection - 14 Mar, 2025
Shilpa Medicare Receives FDA Form 483 Observation - 08 Mar, 2025
Shilpa Medicare Receives USFDA Observation Notice - 07 Mar, 2025
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Netprofit is up for the last 3 quarters, 14.06 Cr → 31.78 Cr (in ₹), with an average increase of 32.6% per quarter
Price Rise
In the last 1 year, SHILPAMED stock has moved up by 37.2%
FII Holding Up
Foreign Institutions have increased holdings from 9.58% to 9.90% in Dec 2024 quarter
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 61.7% return, outperforming this stock by 24.5%
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 121.9% return, outperforming this stock by 66.0%
MF Holding Down
Mutual Funds have decreased holdings from 5.09% to 4.89% in Dec 2024 quarter
Revenue Fall
Revenue is down for the last 2 quarters, 348.79 Cr → 320.79 Cr (in ₹), with an average decrease of 8.0% per quarter
Promoter Holding Down
Promoters have decreased holdings from 44.33% to 44.23% in Dec 2024 quarter
Retail Holding Down
Retail Investor have decreased holdings from 37.90% to 37.60% in Dec 2024 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 44.23% | ||
Foreign Institutions | 9.9% | 3.35 | |
Mutual Funds | 4.89% | ||
Retail Investors | 37.6% | ||
Others | 3.37% | 9.02 |
Shilpa Medicare in the last 5 years
Lowest (-6579.29x)
March 28, 2024
Industry (50.70x)
March 17, 2025
Today (67.35x)
March 17, 2025
Highest (503.73x)
February 21, 2023
Shilpa Medicare Ltd’s net profit jumped 593.89% since last year same period to ₹31.78Cr in the Q3 2024-2025. On a quarterly growth basis, Shilpa Medicare Ltd has generated 77.15% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending March 2022, Shilpa Medicare Ltd has declared dividend of ₹1.10 - translating a dividend yield of 0.35%.
Read More about DividendsBearish
Neutral
Bullish
Shilpa Medicare Ltd is currently in a Bearish trading position according to technical analysis indicators.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹6,164.74 Cr | 19.5% | 0.53 | ₹31 Cr | ₹1,151 Cr | |
BUY | ₹28,896.94 Cr | 157.81% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
BUY | ₹13,639.27 Cr | 49.71% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
NA | ₹3,805.02 Cr | 3.66% | 0.79 | -₹388 Cr | ₹75 Cr | |
BUY | ₹12,694.97 Cr | 35.54% | 0.68 | ₹218 Cr | ₹1,296 Cr |
Organisation | Shilpa Medicare |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Shilpa Medicare Ltd share price today stands at ₹676.5, Open: ₹676.8, Previous Close: ₹630.4, High: ₹710.9, Low: ₹628.3, 52 Week High: ₹959.5, 52 Week Low: ₹397.95.
Today's traded volume of Shilpa Medicare Ltd(SHILPAMED) is 12.76L.
Today's market capitalisation of Shilpa Medicare Ltd(SHILPAMED) is ₹6164.74Cr.
Shilpa Medicare Ltd (SHILPAMED) share price is ₹676.5. It is down -29.49% from its 52 Week High price of ₹959.5
Shilpa Medicare Ltd (SHILPAMED) share price is ₹676.5. It is up 70.00% from its 52 Week Low price of ₹397.95